Literature DB >> 25579320

Therapeutic uses of melatonin and melatonin derivatives: a patent review (2012 - 2014).

Silvia Rivara1, Daniele Pala, Annalida Bedini, Gilberto Spadoni.   

Abstract

INTRODUCTION: Melatonin is a neurohormone involved in the regulation of circadian rhythms, with potent antioxidant activity. It has a wide functional repertoire, with effects almost on all tissues and organs. It is mainly used as a dietary supplement for sleep regulation and re-synchronization of disrupted circadian rhythms. Melatonin has very low toxicity, but some pharmacokinetic issues, such as limited oral bioavailability and short half-life, limit its tissue availability. AREAS COVERED: Patents and patent applications from 2012 to September 2014 in which melatonin or synthetic analogues are claimed for the prevention or treatment of pathological conditions. EXPERT OPINION: Melatonin is considered a valuable substance that can be safely administered for the prevention and treatment of many diverse diseases. A major trend in 2012 - 2014 patents is the co-administration of melatonin with other drugs to increase the efficacy of the treatment and reduce side-effects. Two different actions have been combined in hybrid ligands (e.g., melatonin-tamoxifen and melatonin-tacrine derivatives). Further experimental evidence is needed to support the usefulness of these approaches. The number of new melatonin analogues has shown a marked decrease in the past 3 years, with claimed applications mainly as hypnotic or antioxidant agents.

Entities:  

Keywords:  MT1 receptor; MT2 receptor; TIK-301; agomelatine; antioxidant activity; controlled-release formulation; melatonin; radical scavenger; ramelteon; tasimelteon

Mesh:

Substances:

Year:  2015        PMID: 25579320     DOI: 10.1517/13543776.2014.1001739

Source DB:  PubMed          Journal:  Expert Opin Ther Pat        ISSN: 1354-3776            Impact factor:   6.674


  8 in total

Review 1.  The role of melatonin in Multiple Sclerosis.

Authors:  Charalampos Skarlis; Maria Anagnostouli
Journal:  Neurol Sci       Date:  2019-12-16       Impact factor: 3.307

Review 2.  Systems Chronotherapeutics.

Authors:  Annabelle Ballesta; Pasquale F Innominato; Robert Dallmann; David A Rand; Francis A Lévi
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

3.  What's next for chronobiology and drug discovery.

Authors:  Zheng Chen
Journal:  Expert Opin Drug Discov       Date:  2017-09-11       Impact factor: 6.098

4.  Vesicular melatonin efficiently downregulates sodium fluoride-induced rat hepato- and broncho-TNF-α, TGF-β expressions, and associated oxidative injury: a comparative study of liposomal and nanoencapsulated forms.

Authors:  Suvomoy Sana; Swarupa Ghosh; Nirmalendu Das; Sibani Sarkar; Ardhendu Kumar Mandal
Journal:  Int J Nanomedicine       Date:  2017-05-29

Review 5.  Melatonin: From Pharmacokinetics to Clinical Use in Autism Spectrum Disorder.

Authors:  Sébastien Lalanne; Claire Fougerou-Leurent; George M Anderson; Carmen M Schroder; Tali Nir; Sylvie Chokron; Richard Delorme; Bruno Claustrat; Eric Bellissant; Solenn Kermarrec; Patricia Franco; Laure Denis; Sylvie Tordjman
Journal:  Int J Mol Sci       Date:  2021-02-02       Impact factor: 5.923

Review 6.  Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms.

Authors:  Josiel Mileno Mack; Marissa Giovanna Schamne; Tuane Bazanella Sampaio; Renata Aparecida Nedel Pértile; Pedro Augusto Carlos Magno Fernandes; Regina P Markus; Rui Daniel Prediger
Journal:  Oxid Med Cell Longev       Date:  2016-10-18       Impact factor: 6.543

7.  Antiproliferative and pro-apoptotic activity of melatonin analogues on melanoma and breast cancer cells.

Authors:  Giuliana Gatti; Valeria Lucini; Silvana Dugnani; Angela Calastretti; Gilberto Spadoni; Annalida Bedini; Silvia Rivara; Marco Mor; Gianfranco Canti; Francesco Scaglione; Annamaria Bevilacqua
Journal:  Oncotarget       Date:  2017-08-10

8.  Characterization of the various functional pathways elicited by synthetic agonists or antagonists at the melatonin MT1 and MT2 receptors.

Authors:  Céline Legros; Clémence Dupré; Chantal Brasseur; Anne Bonnaud; Olivier Bruno; Damien Valour; Preety Shabajee; Adeline Giganti; Olivier Nosjean; Terrence P Kenakin; Jean A Boutin
Journal:  Pharmacol Res Perspect       Date:  2019-12-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.